Search

Author/Creator Bollani, S.

1. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. (8th October 2016)

Authors:
Persico, M.; Rendina, M.; Di Marco, V.; Aghemo, A.; Brunetto, M.; Ciancio, A.; Zuin, M.; Andreone, P.; Villa, E.; Calvaruso, V.; De Nicola, S.; Coco, B.; Aglitti, A.; Toshina, Y.; Giorgini, A.; Conti, F.; Marzi, L.; Lleo, A.; Bollani, S.; Di Leo, A.
Journal:
Digestive and liver disease
Issue:
Volume 48(2016)Supplement 3
Page Start:
e233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma. Issue 12 (3rd May 2018)

Authors:
Persico, M.; Aglitti, A.; Aghemo, A.; Rendina, M.; Lleo, A.; Ciancio, A.; Di Marco, V.; Lampertico, P.; Brunetto, M. R.; Zuin, M.; Andreone, P.; Villa, E.; Troshina, G.; Calvaruso, V.; Degasperi, E.; Coco, B.; Giorgini, A.; Conti, F.; Di Leo, A.; Marzi, L.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 12(2018)
Page Start:
1705
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study. Issue 1 (February 2018)

Authors:
Lleo, A.; Aglitti, A.; Ciancio, A.; Di Marco, V.; Aghemo, A.; Lampertico, P.; Brunetto, M.R.; Zuin, M.; Andreone, P.; Villa, E.; Troshina, G.; Calvaruso, V.; Degasperi, E.; Coco, B.; Giorgini, A.M.; Conti, F.; Di Leo, A.; Marzi, L.; Boccaccio, V.; Bollani, S.
Journal:
Digestive and liver disease
Issue:
Volume 50:Issue 1(2018)Supplement
Page Start:
34
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Undetectable HCV‐RNA at treatment‐week 8 results in high‐sustained virological response in HCV G1 treatment‐experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Issue 5 (14th October 2014)

Authors:
Bruno, S.; Bollani, S.; Zignego, A. L.; Pascasio, J. M.; Magni, C.; Ciancio, A.; Caremani, M.; Mangia, A.; Marenco, S.; Piovesan, S.; Chemello, L.; Babudieri, S.; Moretti, A.; Gea, F.; Colletta, C.; Perez‐Alvarez, R.; Forns, X.; Larrubia, J. R.; Arenas, J.; Crespo, J.
Journal:
Journal of viral hepatitis
Issue:
Volume 22:Issue 5(2015)
Page Start:
469
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗